The study included 1,306 patients (darolutamide: 651, placebo: 655), with 86.1% having metastatic disease at the time of diagnosis. At the primary analysis’s data cutoff date (October 25, 2021), the risk of death in the darolutamide group was 32.5% lower than in the placebo group. Adverse events were comparable in both groups, and the most common adverse events (occurring in 10% of patients) were most common during the overlapping docetaxel treatment period in both groups.

A total of 168 patients were randomly assigned to receive tumor-infiltrating lymphocytes (TILs) (84 patients) or ipilimumab (84 patients). The median progression-free survival in the TIL group was 7.2 months and 3.1 months in the ipilimumab group; 49% and 21% of the patients, respectively, had an objective response. The TIL group had a median overall survival of 25.8 months, while the ipilimumab group had a median overall survival of 18.9 months.

After 5 years of denosumab therapy, this patient has had no fractures and bone density scores have improved. You plan to discontinue denosumab. What else should be done?

Are the findings a result of bacterial endocarditis? Resurgent sarcoidosis? An opportunistic fungal pulmonary invasion? Review the workup and cast your vote on what you think the diagnosis is.

A double-blind, placebo-controlled randomized clinical trial including people with COPD and chronic breathlessness was conducted at 20 Australian medical centers. One-hundred sixty participants were randomized to oral extended-release morphine versus placebo. The change in the intensity of worst breathlessness at week 1 was not significantly different between the morphine group and the placebo group.

The excess mortality amounts to 150,000 to 470,000 deaths. Mortality rates were lower, and in keeping with peer country comparisons, in the 10 states with highest vaccination levels.